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Glucagon-Like Peptide-1 receptor agonists (GLP-1RAs), approved as glucose-lowering drugs for the treatment of type 2 diabetes,
have also been shown to reduce body weight. An extensive Medline, Cochrane database, and Embase search for “exenatide,”
“liraglutide,”“albiglutide,”“semaglutide,”and“lixisenatide”wasperformed,collectingallrandomizedclinicaltrialsonhumansup
to December 15, 2011, with a duration of at least 24 weeks, comparing GLP-1 receptor agonists with either placebo or active drugs.
Twenty two (7,859 patients) and 7 (2,416 patients) trials with available results on body weight at 6 and 12 months, respectively,
were included. When compared with placebo, GLP-1RAs determine a reduction of BMI at 6 months of −1.0 [−1.3; −0.6]kg/m2.
Considering the average BMI at baseline (32.4kg/m2) these data means a weight reduction of about 3% at 6 months. This result
could seem modest from a clinical standpoint; however, it could be aﬀected by many factors contributing to an underestimation of
the eﬀect of GLP-1RA on body weight, such as non adequate doses, inclusion criteria, eﬃcacy of GLP-1RA on reducing glycosuria,
and association to non-pharmacological interventions not speciﬁcally aimed to weight reduction.
1.Introduction
Mostdrugsdevelopedforthetherapyofobesityhavefailedto
show a suﬃcient eﬃcacy and safety for long-term treatment.
In particular, agents which stimulate energy expenditure
(e.g., thyroid hormones, sympathoadrenergic drugs, or
sibutramine) do not have an adequate cardiovascular safety,
whereas centrally acting anorexants either are ineﬀective in
the long term (e.g., serotonin reuptake inhibitors) or show
neuropsychiatric adverse eﬀects (e.g., amphetamine deriva-
tives or cannabinoid receptor antagonists) [1]. As a result,
orlistat, which inhibits lipid absorption, is the only available
drug for obesity in many countries. Even for drugs which do
not show relevant problems of long-term safety, such as orli-
stat, the unsatisfactory tolerability proﬁle limits clinical use.
Glucagon-like peptide-1 (GLP-1) is a gastrointestinal
hormone, produced mainly in the postprandial phase, which
stimulates insulin secretion and inhibits glucagon release in
a dose-dependent fashion [2]. Due to this properties, the
hormone reduces hyperglycemia without inducing hypo-
glycemia in patients with type 2 diabetes [3]. The rapid inac-
tivationofGLP-1invivoandtheconsequentshorthalf-life(a
few minutes after subcutaneous administration) prevents its
therapeutic use. Long-acting GLP-1 receptor agonists, which
canbeadministeredviasubcutaneousinjectiononceortwice
a day or once a week, have been developed as glucose-
lowering drugs for the treatment of type 2 diabetes [4], but
they have also been shown to reduce body weight [5, 6]. The
eﬀects of GLP-1 and its agonists on body weight appears to
be due to a reduction in food intake, mainly determined by a
direct central (hypothalamic) eﬀect of the hormone [7]. The
stimulation of GLP-1 receptor also retards gastric emptying;
thislattereﬀectisagaindue,atleastpartly,toacentralaction,
mediated via the autonomous nervous system [8]. One of
thesideeﬀectofGLP-1receptoragonists,nausea(sometimes
associated with vomiting), could contribute to the weight2 Experimental Diabetes Research
reducing eﬀect; however, weight loss has also been observed
when analyzing separately patients who do not report nausea
[8].
In fact, some drugs of this class (i.e., liraglutide and
long-acting exenatide) are currently under development for
the treatment of obesity [9–12]. A phase II, 20-week trial
enrolling patients without diabetes showed that liraglutide
has a higher eﬃcacy than orlistat in promoting weight
loss [13]. Another longer-term (52 weeks) trial with same
molecule, the results of which have not been published in
full but partly disclosed [14], conﬁrms that liraglutide is
an interesting option for the treatment of obesity. Another
molecule of the same class, exenatide, has been reported
to induce a signiﬁcant weight loss in a 24-week placebo-
controlled trial [15]. Most of what is known on the eﬀect
of GLP-1 receptor agonists on body weight comes from
clinical trials performed on patients with type 2 diabetes,
with glucose control as the principal endpoint. Currently
ongoing trials enrolling subjects with obesity and without
diabetes will provide, in due time, further information. In
the meanwhile, a systematic evaluation of data collected in
studiesontype2diabetescanprovideamoredeﬁnedpicture
of what we can realistically expect from GLP-1 receptor
agonists as weight-reducing agents.
Ar e c e n tm e t a - a n a l y s i sh a ss h o w naw e i g h tl o s so f
approximately 3% at endpoint in available published trials,
with a duration ranging from 20 to 52 weeks [6]. This
analysis does not provide information on the time-course of
weight loss with GLP-1 receptor agonists. Furthermore, no
distinctionismadebetweenplacebo-andactivecomparator-
controlled trials, with some of the comparators (i.e., insulin,
thiazolidinediones, and sulfonylureas) possibly inducing
weight gain. Aim of the present meta-analysis is to assess the
eﬀects of GLP-1 receptor agonists on body weight at 6 and
12 months of treatment, separating placebo-controlled trials
from comparisons with active drugs. Furthermore, a meta-
regression analysis will be performed to explore predictors of
weight change during treatment.
2. Methods
The meta-analysis was reported following the PRISMA
checklist [16].
2.1. Data Sources, Searches, and Extraction. An extensive
Medline, Cochrane database, and Embase search for all ar-
ticles in English using the keywords “exenatide”, “lirag-
lutide”, “albiglutide”, “semaglutide”, and “lixisenatide” was
performed collecting all randomized clinical trials on
humans up to December 15, 2011. Completed but still
unpublished trials were identiﬁed through a search of http://
www.clinicaltrials.gov/ website. FDA (http://www.fda.gov/)
and European Medicines Agency (EMA, http://www.ema
.europa.eu/) reviews of approved drugs, as well as published
infor-mation provided to FDA in response to queries during
the approval process, were also searched for retrieval of un-
publishedtrials.Resultsofthosetrialswereretrieved,ifavail-
able, on http://www.novonordisk-trials.com/ or http://www
.clinicaltrials.org/. For unpublished and published trials
which were not exhaustively disclosed, an attempt was made
(through e-mail) to contact principal investigators in order
to retrieve missing data. For all published trials, results
reported in papers were used as the primary source of infor-
mation, when available.
The identiﬁcation of relevant abstracts, the selection of
studies based on the criteria described previously, and the
subsequent data extraction were performed independently
by two of the authors (E. Mannucci, M. Monami), and
conﬂicts these resolved by the third investigator (N. Mas-
chionni).
2.2. Study Selection. A meta-analysis was performed includ-
ing all randomized clinical trials, with a duration of at least
24 weeks, comparing full therapeutic doses Glucagon-like
Peptide-1 (GLP-1) receptor agonists (i.e., at least 1.8mg/day
liraglutide, 20μg/day for exenatide b.i.d., 2mg/day for
exenatide once weekly) and with placebo or other active
drugs. Trials with a shorter duration were excluded, due to
the fact that they could not yield relevant information on
body weight reduction. No review protocol was published
elsewhere. Trials without any information on body mass
index (BMI) at 6 or 12 months were also excluded.
2.3. Quality Assessment. The quality of trials was assessed
using some of the parameters proposed by Jadad et al. [17].
Thescorewasnotusedasacriterionfortheselectionoftrials,
whereas some items were used only for descriptive purposes.
2.4. Data Synthesis and Analysis. The principal outcome was
theeﬀectoffulltherapeuticdosesofGLP-1receptoragonists,
compared with other hypoglycemic agents or placebo, on
BMI at 6 months and 12 months (when available). Between-
group diﬀerences in endpoint BMI were assessed as a
measure of treatment eﬀect, without considering diﬀer-
ences from baseline. Secondary outcomes included glycated
hemoglobin (HbA1c) at 6 and 12 months. Separate analyses
were performed for trials with diﬀerent GLP-1 receptor
agonists and with diﬀerent comparators, whenever possible.
Furthermore, separate analyses were performed for trials
with diﬀerent principal endpoints. Metaregression analysis
was performed on placebo-controlled trials, in order to
identify possible predictors of weight loss.
Heterogeneity was calculated using the I2 statistics.
Weighted mean diﬀerences were calculated for BMI and
HbA1c at 6 and 12 months, and a random eﬀects model was
used for the meta-analysis. Publication/disclosure bias was
estimated separately for placebo-controlled trials and studies
versus active comparators, using Kendall’s tau without
continuity correction, and one-sided P,w e r ec a l c u l a t e d ,
together with the fail-safe N, and Funnel plot analysis. All
those analyses were performed using Comprehensive Meta-
analysis Version 2, Biostat, (Englewood, NJ, USA).
3. Results
The trial ﬂow summary is reported in Figure 1.T r i a l sw i t h
available results on body mass index at 6 months were 21Experimental Diabetes Research 3
Medline/unpublished
n = 127/157
Not randomized trials
n = 19/22
Non humans
n = 1/0
No external comparison
n = 4/7
Short duration
n = 55/77
Duplicate
n = 15/3
Already published on medline
n = 0/25
n = 12/23
Fulﬁlling all inclusion criteria
n = 21/0
Included
N = 21
BMI at 6 months not available
Figure 1: Trial ﬂow summary.
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Figure 2: Funnel plot for bias/disclosure publication.
(19 of which in patients with diabetes), whereas those with
data at one year were 7 (6 of which on diabetes); the
characteristics of those studies are summarized in Table 1.
Funnel plot analysis on 6-month trials on diabetes (Figure 2)
didnotrevealanymajorpublication/disclosurebiasforBMI,
as conﬁrmed by Kendall’s tau (t = 0.14, P = 0.36) and fail-
safeN (numberofmissingstudiesthatwouldbringP>0.05:
733). I2 for BMI at 6 months was 83.6 (P<0.001).
3.1. Results at 6 Months. Only two trials [15, 18]i n
subjects with obesity not associated with diabetes reported
outcomes on body weight of exenatide at 6 months (with
a signiﬁcant (P = 0.002) BMI reduction of 1.6 (0.6–2.5)
kg/m2 in comparison with placebo). One further trial, which
enrolled patients with type 2 diabetes, had been designed
for the assessment of weight reduction with exenatide as the
principal outcome [19], with similar results.
In the 19 trials performed in patients with diabetes,
GLP-1 receptor agonists were associated with a signiﬁcantly
lower BMI at 6 months in comparison with placebo and
with any active glucose-lowering agent, with the exception
of the only 2 available head-to-head comparisons with
thiazolidinediones. No diﬀerences in the weight-reducing
eﬀects were observed between exenatide and liraglutide
(Figure 3(a)). A subgroup analysis of placebo-controlled
trials was performed on the basis of the minimum BMI
chosen as inclusion criterion; in trials excluding (N = 4)
or including (N = 5) nonoverweight (BMI < 25kg/m2),
the diﬀerence in 6-month BMI between active treatment
and control groups was −1.0 [−1.6; −0.4] and −0.8 [−1.3;
−0.3]kg/m2,r e s p e c t i v e l y( b o t hP<0.001).
For18outof19ofthosetrials,theprincipalendpointwas
HbA1c, which was signiﬁcantly reduced by GLP-1 receptor
agonists in comparison with placebo, DPP4 inhibitors,
and thiazolidinediones, whereas diﬀerences with respect to
sulfonylureas and insulin were not statistically signiﬁcant
(Figure 3(b)).
Metaregression analysis was performed on all placebo-
controlled trials, including those on nondiabetic individuals,
irrespective of the principal endpoint of the study. In the
11 available trials, mean baseline BMI, age, and duration of
diabetes (in the 9 trials on patients with diabetes) were not
signiﬁcantly correlated with treatment eﬀect on BMI.
3.2. Results at 12 Months. Results on BMI at 12 months were
available in 7 trials, 6 of which were performed in patients
with diabetes. The only one trial [14] enrolling subjects
without diabetes, which had weight loss as its principal
endpoint, liraglutide, induced a signiﬁcant reduction of
weightincomparisonwithplacebo(−1.2[−2.3;−0.1]kg/m2
in 1-year BMI; P = 0.04). The results of the other 6 trials, all
with active comparators, are summarized in Table 2. In these
studies, a further reduction of body weight was observed
after the ﬁrst six months of treatment. Similar results were
obtained when the only trial which did not report 6-month
BMI [14] was excluded from the analysis (data not shown).
4. Discussion
T h ef e wa v a i l a b l et r i a l sd e s i g n e dw i t hw e i g h tl o s sa st h e
principal endpoint and enrolling nondiabetic patients with
obesity have shown that GLP-1 receptor agonists have a
potential use as drugs for the treatment of overweight
[14, 15]. Similar results were obtained in a trial on over-
weight patients with polycystic ovary syndrome, in which
restoration of menstrual cycles was the principal endpoint
[20]. The much wider evidence collected in subjects with
type 2 diabetes conﬁrms this eﬀect, as previously reported
[6, 18]. This action is consistent across trials, and it cannot
be attributed to selective reporting as shown by Funnel4 Experimental Diabetes Research
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Table 2: Weighted mean diﬀerences in 6- and 12-month BMI between GLP-1 receptor agonists and diﬀerent active comparators.
Number
of trials 6-month BMI P 12-month BMI P
Overall 6 −1.2 [−1.5; −0.8] <0.001 −1.9 [−3.0; −0.8] <0.001
DPP-4 inhibitors 1 −1.6 [−2.6; −0.8] <0.001 −1.7 [−2.7; −0.7] 0.001
Sulphonylureas 3 −1.4 [−2.4; −0.7] 0.001 −2.3 [−4.2; −0.5] 0.012
Insulin 2 −0.7 [−1.4; 0.0] 0.048 −1.5 [−2.1; −0.8] <0.001
MD LL,95% CI UL,95% CI
Thiazolidinediones
Sulfonylureas
Exenatide
Liraglutide
Insulin
Exenatide
Liragl./Exen. LAR
Placebo
Exenatide
Liraglutide
2
2
4
2
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Figure 3: Weighted mean diﬀerences in 6-month BMI (a) and HbA1c (b) between GLP-1 receptor agonists and diﬀerent active comparators
or placebo, in trials performed in type 2 diabetic patients. MD: weighted mean diﬀerences; LL: lower limits; UL: upper limits.6 Experimental Diabetes Research
plot analysis and Kendall’s tau calculation. GLP-1 receptor
agonists have a beneﬁcial eﬀect on body weight not only in
comparisons with drugs that induce weight gain (such as
insulin or sulfonylureas) but also with respect to placebo.
Theonlyexceptionisrepresentedbydirectcomparisonswith
thiazolidinediones: in this case, despite a mean diﬀerence
in 6-month BMI similar to that observed for other active
comparators, the statistical signiﬁcance is not reached, due
to the small number of available trials.
In order to evaluate the weight reducing eﬀect of
GLP-1 receptor agonists, the most interesting results are
those obtained in placebo-controlled trials, which allow to
discriminate the beneﬁcial action of these drugs from the
adverse eﬀects on body weight of other glucose-lowering
agents. In these studies, the mean weight loss at 6 months
is 1.0kg/m2; considering that the average BMI at baseline
is about 33.9kg/m2, this means that the actual ponderal
reductionisinthe3%range.Theestimatedweightlossseems
to be larger than that reported in a previous meta-analysis
[6]; this result could be due to the exclusion of patients
treated with submaximal doses of GLP-1 receptor agonists.
This result could seem modest from a clinical standpoint;
however, several factors should be considered. In all trials on
patients with diabetes except one the principal endpoint was
the improvement in HbA1c, and not weight loss. This means
that patients were selected on the basis of unsatisfactory
glucose control, and not for their overweight; the minimum
BMI for inclusion was not speciﬁed in some studies, and
ranged from 25 to 45kg/m2 in the others, meaning that,
in all trials, part of the patients enrolled were not actually
obese. Notably, those trials that excluded normal-weight
subjectsshowedagreatereﬀectofGLP-1receptoragonistson
weight loss. Furthermore, patients with diabetes could have
greater diﬃculties in losing weight than similarly overweight
subjects with normal glucose tolerance. In those who had
elevated HbA1c at baseline, the reduction of glycosuria
determined by drug treatment could have been an obstacle
toweightloss.Finally,thenonpharmacologicalinterventions
associatedtodrugsintrialsforglycemiccontrolintype2dia-
b e t e sa r en o ts p e c i ﬁ c a l l ya i m e da tw e i g h tr e d u c t i o n .A l lt h e s e
factors could have contributed to an underestimation of the
eﬀect of GLP-1 receptor agonists on body weight. It should
also be recognized that weight loss in clinical trials could
be quite diﬀerent from that obtained in real-life conditions.
The selection of patients with greater compliance and the
more accurate follow-up produces a greater weight loss from
baseline in randomized clinical trials. On the other hand, for
the same reasons, as long as the between-group diﬀerences
are assessed, as in the present study, the lifestyle/dietary
intervention associated with drug treatment in randomized
trials can partly mask the actual eﬀect of the drug.
It should also be considered that treatment with GLP-1
receptor agonists could have some further beneﬁcial eﬀects
on other metabolic alterations of obese patients (e.g., insulin
resistance, risk of diabetes, blod pressure, etc.), beyond
weight loss. The assessment of those eﬀects was not among
the aims of the present meta-analysis.
The eﬀect of GLP-1 and its receptor agonists on food
intake and body weight is dose dependent [13]. For this
reason, it is possible that doses needed for the treatment of
obesity are higher than those indicated for type 2 diabetes.
For example, liraglutide 3.0mg/day induces a greater weight
loss than 1.8mg/day, whereas no additional eﬀect on blood
g l u c o s ei se x p e c t e do v e r1 . 8m g / d a y[ 13]. Obviously, at least
some of the adverse eﬀects of these drugs (e.g., nausea
and vomiting) are also dose-dependent and they could be
ampliﬁed by the increase in daily doses. In the case that re-
commended doses for obesity exceed in a relevant manner
those for diabetes, the safety proﬁle of GLP-1 receptor ago-
nists, which is satisfactory when they are used in the treat-
ment of type 2 diabetes, should be veriﬁed on a suﬃciently
wide amount of data.
Some interesting information can be obtained from the
analysis of data collected in trials on type 2 diabetes with a 1-
year follow-up; in fact, the eﬀect of GLP-1 receptor agonists
at 1 year seems to be larger than that observed, in the same
trials, after 6 months of treatment. The number of studies
is limited, and none of them includes a comparison with
placebo; in fact, a longer-term treatment without any active
drug would be unethical in patients with unsatisfactory
controlofdiabetes. Activecomparisonscanbemisleading, as
the comparators often induce weight gain (e.g., insulin, sul-
fonylureas,thiazolidinediones);thismeansthattheincreased
diﬀerence between GLP-1 receptor agonists and control
groups at 1 year could be partly due to weight gain induced
by comparators. Despite these limitations, the possibility
that the maximum eﬀect of GLP-1 receptor agonists on
body weight is reached after 6 months should be considered
and taken into account in the design of future clinical
trials.
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